| Literature DB >> 35207691 |
Ching-Nung Wu1,2, Sheng-Dean Luo1,3, Shu-Fang Chen4, Chi-Wei Huang4, Pi-Ling Chiang5, Chung-Feng Hwang1, Chao-Hui Yang1, Chun-Hsien Ho1, Wei-De Cheng1, Chung-Ying Lin2,6,7,8, Yi-Lu Li9,10.
Abstract
The videonystagmography oculomotor test battery is considered useful method for diagnosing vertigo. However, its role in diagnosing central vestibular disorder has not been clarified due to variations in interpretation. Patients (n = 103) with vertigo or dizziness symptoms undergoing the oculomotor tests and brain MRI within 1 month were analyzed. Two otology specialists retrospectively interpreted the oculomotor tests, and three neurology and neuroradiology specialists determined whether central lesions were present on brain MRI. Multivariable logistic regression analysis was performed to determine the factors contributing to discordant interpretation between oculomotor tests and brain MRI. Oculomotor tests predicting central lesions were assessed using principal component analysis. The intra- and inter-rater reliability in oculomotor test interpretation was moderate to good. Age > 60 years and multiple comorbidities were significant predictors of a discordant interpretation between MRI and oculomotor tests. Positive neurological symptoms and a higher oculomotor index (according to saccade (vertical axis), smooth pursuit (horizontal axis), and gaze-evoked nystagmus (horizontal/vertical axes) tests) significantly predicted central vestibular disorder in vertigo patients. Caution is required when interpreting the results of the oculomotor test battery for diagnosis of central lesions in older patients, as well as in those with multiple comorbidities.Entities:
Keywords: central vestibular disorder; gaze evoked nystagmus; principal component analysis; pursuit; saccade
Year: 2022 PMID: 35207691 PMCID: PMC8880333 DOI: 10.3390/jpm12020203
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Figure 1Flow diagram of the overall study design.
Demographic and clinical characteristics of the 103 vertigo patients included in the study.
| Variables | All Patients | Central | Nonspecific | |
|---|---|---|---|---|
|
| 0.794 | |||
| years (IQR) | 60 (49–69) | 61 (48–69) | 60 (49–69) | |
|
| * 0.014 | |||
| Female | 65 (63.1%) | 10 (41.7%) | 55 (69.6%) | |
| Male | 38 (36.9%) | 14 (58.3%) | 24 (30.4%) | |
|
| 0.339 | |||
| Median (IQR) | 24.0 (21.7–25.7) | 24.7 (22.5–26.6) | 23.8 (21.7–25.7) | |
|
| 0.379 | |||
| No | 71 (83.5%) | 11 (91.7%) | 60 (82.2%) | |
| Yes (>30 dB loss) | 14 (16.5%) | 1 (8.3%) | 13 (17.8%) | |
|
| * <0.001 | |||
| No | 78 (75.7%) | 8 (33.3%) | 70 (88.6%) | |
| Yes | 25 (24.3%) | 16 (66.7%) | 9 (11.4%) | |
|
| N/A | N/A | ||
| No | 79 (76.7%) | |||
| Yes | 24 (23.3%) | |||
|
| N/A | N/A | ||
| Cortical and subcortical | 10 (38.5%) | |||
| Brain stem | 10 (38.5%) | |||
| Cerebellar | 5 (19.2%) | |||
| Skull base | 1 (3.8%) | |||
|
| N/A | N/A | ||
| Cerebrovascular accident | 13 (54.2%) | |||
| Tumor | 9 (37.5%) | |||
| Inflammation | 2 (8.3%) | |||
|
| ||||
| Diabetes mellitus | 0.556 | |||
| No | 83 (80.6%) | 18 (75.0%) | 65 (82.3%) | |
| Yes | 20 (19.4%) | 6 (25.0%) | 14 (17.7%) | |
| Hypertension | 0.323 | |||
| No | 52 (50.5%) | 10 (41.7%) | 42 (53.2%) | |
| Yes | 51 (49.5%) | 14 (58.3%) | 37 (46.8%) | |
| Hyperlipidemia | 0.253 | |||
| No | 66 (64.1%) | 13 (54.2%) | 53 (67.1%) | |
| Yes | 37 (35.9%) | 11 (45.8%) | 26 (32.9%) | |
| History of CVA | 0.622 | |||
| No | 97 (94.2%) | 22 (91.7%) | 75 (94.9%) | |
| Yes | 6 (5.8%) | 2 (8.3%) | 4 (5.1%) | |
| Cardiovascular disease | 0.588 | |||
| No | 98 (95.2%) | 24 (100.0%) | 74 (93.7%) | |
| Yes | 5 (4.8%) | 0 (0.0%) | 5 (6.3%) | |
| Accumulated comorbidities | 0.709 | |||
| 0 | 28 (27.2%) | 5 (20.8%) | 23 (29.1%) | |
| 1–2 | 64 (62.1%) | 16 (66.7%) | 48 (60.8%) | |
| ≥3 | 11 (10.7%) | 3 (12.5%) | 8 (10.1%) |
* p < 0.05. Abbreviations: CVA, cerebrovascular accident; IQR, interquartile range; N/A, not applicable.
Validity and reliability of the oculomotor test interpretations of the two specialists.
| Raters | Sensitivity | Specificity | PPV | NPV | Test–Retest Reliability | Inter-Rater Reliability |
|---|---|---|---|---|---|---|
| Dr. A | 54.2% | 67.1% | 33.3% | 82.8% | 0.669 (0.521–0.817) | 0.480 (0.329–0.630) |
| Dr. B | 66.7% | 43.0% | 26.2% | 81.0% | 0.571 (0.413–0.729) |
Abbreviations: NPV, negative predictive value; PPV, positive predictive value.
Demographic and clinical characteristics of patients whose oculomotor tests were consistent and inconsistent with the MRI findings (n = 75).
| Variables | Consistent | Inconsistent | |
|---|---|---|---|
| * <0.001 | |||
| years (IQR) | 55 (41.5–63.5) | 69 (52–76) | |
|
| 0.968 | ||
| Female | 30 (68.2%) | 21 (67.7%) | |
| Male | 14 (31.8%) | 10 (32.3%) | |
|
| 0.378 | ||
| Median (IQR) | 23.2 (20.6–25.5) | 24.0 (21.8–25.9) | |
|
| 0.804 | ||
| No | 33 (86.8%) | 24 (88.9%) | |
| Yes (>30 dB loss) | 5 (13.2%) | 3 (11.1%) | |
|
| 0.640 | ||
| No | 36 (81.4%) | 24 (77.4%) | |
| Yes | 8 (18.6%) | 7 (22.6%) | |
|
| 0.478 | ||
| No | 34 (77.3%) | 26 (83.9%) | |
| Yes | 10 (22.7%) | 5 (16.1%) | |
|
| 0.327 | ||
| Cortical and subcortical | 3 (27.3%) | 1 (20.0%) | |
| Brain stem | 6 (54.6%) | 1 (20.0%) | |
| Cerebellar | 2 (18.1%) | 3 (60.0%) | |
|
| 0.213 | ||
| Cerebrovascular accident | 7 (70.0%) | 2 (40.0%) | |
| Tumors | 3 (30.0%) | 1 (20.0%) | |
| Inflammation | 0 (0.0%) | 2 (40.0%) | |
|
| |||
| Diabetes mellitus | 0.468 | ||
| No | 37 (84.1%) | 24 (77.4%) | |
| Yes | 7 (15.9%) | 7 (22.6%) | |
| Hypertension | 0.204 | ||
| No | 25 (56.8%) | 13 (41.9%) | |
| Yes | 19 (43.2%) | 18 (58.1%) | |
| Hyperlipidemia | 0.240 | ||
| No | 30 (68.2%) | 17 (54.8%) | |
| Yes | 14 (31.8%) | 14 (45.2%) | |
| History of CVA | 0.067 | ||
| No | 43 (97.7%) | 27 (87.1%) | |
| Yes | 1 (2.3%) | 4 (12.9%) | |
| Cardiovascular disease | 0.160 | ||
| No | 43 (97.7%) | 28 (90.3%) | |
| Yes | 1 (2.3%) | 3 (9.7%) | |
| Accumulated comorbidities | * 0.017 | ||
| 0 | 15 (34.1%) | 3 (9.7%) | |
| 1–2 | 27 (61.3%) | 23 (74.2%) | |
| ≥3 | 2 (4.6%) | 5 (16.1%) |
* p < 0.05. Abbreviations: CVA, cerebrovascular accident; IQR, interquartile range.
Univariate and multivariate analyses of factors predicting discordance between the interpretations of oculomotor tests and brain MRI (n = 75).
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
|
| ||||
| <60 years old (n = 34) | 1 | 1 | ||
| ≥60 years old (n = 41) | 4.15 (1.52–11.34) | * 0.006 | 3.09 (1.04–9.14) | * 0.042 |
|
| ||||
| Female | 1 | 1 | ||
| Male | 1.02 (0.38–2.73) | 0.968 | 0.91 (0.30–2.83) | 0.877 |
|
| 1.05 (0.94–1.17) | 0.407 | ||
|
| ||||
| No (n = 57) | 1 | |||
| Yes (>30 dB loss) (n = 8) | 0.83 (0.18–3.79) | 0.805 | ||
|
| ||||
| No | 1 | 1 | ||
| Yes | 1.31 (0.42–4.10) | 0.640 | 0.99 (0.28–3.56) | 0.991 |
|
| ||||
| No | 1 | |||
| Yes | 0.65 (0.20–2.15) | 0.484 | ||
|
| ||||
| Diabetes mellitus | ||||
| No | 1 | |||
| Yes | 1.54 (0.48–4.95) | 0.467 | ||
| Hypertension | ||||
| No | 1 | |||
| Yes | 1.82 (0.72–4.72) | 0.206 | ||
| Hyperlipidemia | ||||
| No | 1 | |||
| Yes | 1.77 (0.68–4.56) | 0.241 | ||
| History of CVA | ||||
| No | 1 | |||
| Yes | 6.37 (0.68–60.05) | 0.106 | ||
| Cardiovascular disease | ||||
| No | 1 | |||
| Yes | 4.61 (0.46–46.54) | 0.195 | ||
| Accumulated Comorbidities | ||||
| 0 | 1 | 1 | ||
| 1–2 | 4.26 (1.10–16.57) | * 0.037 | 2.89 (0.65–12.92) | 0.164 |
| ≥3 | 12.50 (1.60–97.64) | * 0.016 | 8.31 (0.96–71.71) | 0.054 |
* p < 0.05. Abbreviations: CVA, cerebrovascular accident; OR, odds ratio.
Univariate analysis of oculomotor signals predicting abnormal brain MRI. The “factor score” was calculated via principal component analysis of significantly predictive tests (n = 103).
| Oculomotor Signals | Univariate | Factor | |
|---|---|---|---|
|
| |||
| Horizontal | |||
| No | 1 | ||
| Yes | 1.85 (0.71–4.83) | 0.206 | |
| Vertical | |||
| No | 1 | ||
| Yes | 3.58 (1.29–9.98) | * 0.015 | 0.4981 |
|
| |||
| Horizontal | |||
| No | 1 | ||
| Yes | 3.39 (1.26–9.09) | * 0.016 | 0.5120 |
| Vertical | |||
| No | 1 | ||
| Yes | 2.25 (0.84–6.03) | 0.106 | |
|
| |||
| Horizontal | |||
| No | 1 | ||
| Yes | 3.06 (1.19–7.85) | * 0.020 | 0.5228 |
| Vertical | |||
| No | 1 | ||
| Yes | 4.72 (1.72–12.99) | * 0.003 | 0.4653 |
|
| |||
| No | 1 | ||
| Yes | 1.22 (0.44–3.36) | 0.707 | |
|
| |||
| No | 1 | ||
| Yes | 2.32 (0.83–6.48) | 0.108 |
* p < 0.05. “no”: no signal was labeled by both raters; “yes”: signal was labeled by either rater. Abbreviations: OKAN, optokinetic afternystagmus; OPK, optokinetic nystagmus; OR, odds ratio.
Figure 2Principal component analysis of oculomotor tests. (A) The scree plot shows that the anchor of the graph where the eigenvalues appear to level off lies in PC2. (B) The biplot shows the projections of the oculomotor tests on PC1 and PC2 with the four significantly predictive dimensions. PC = principal component.
Univariate and multivariate analyses of factors predicting abnormal brain MRI (n = 103).
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
|
| ||||
| <60 years-old (n = 48) | 1 | 1 | ||
| ≥60 years-old (n = 55) | 1.30 (0.52–3.27) | 0.581 | 0.73 (0.20–2.68) | 0.632 |
|
| ||||
| Female | 1 | 1 | ||
| Male | 3.21 (1.25–8.23) | * 0.015 | 2.85 (0.82–9.90) | 0.100 |
|
| ||||
| Median (IQR) | 1.03 (0.93–1.15) | 0.528 | ||
|
| ||||
| No | 1 | |||
| Yes (>30 dB loss) | 0.42 (0.05–3.54) | 0.425 | ||
|
| ||||
| No | 1 | 1 | ||
| Yes | 15.56 (5.20–46.56) | * <0.001 | 13.45 (4.00–45.12) | * <0.001 |
|
| ||||
| Diabetes mellitus | ||||
| No | 1 | |||
| Yes | 1.55 (0.52–4.60) | 0.432 | ||
| Hypertension | ||||
| No | 1 | |||
| Yes | 1.59 (0.63-4.00) | 0.326 | ||
| Hyperlipidemia | ||||
| No | 1 | |||
| Yes | 1.73 (0.68-4.37) | 0.251 | ||
| History of CVA | ||||
| No | 1 | |||
| Yes | 1.71 (0.29-9.94) | 0.553 | ||
| | ||||
| 0 | 1 | 1 | ||
| 1–2 | 1.53 (0.50–4.70) | 0.455 | 0.56 (0.11–2.79) | 0.481 |
| ≥3 | 1.73 (0.33–8.91) | 0.515 | 0.47 (0.05–4.44) | 0.506 |
| | ||||
| <50% | 1 | 1 | ||
| >50% | 4.65 (1.66–12.99) | * 0.003 | 4.59 (1.28–16.44) | * 0.019 |
* p < 0.05. Abbreviations: CVA, cerebrovascular accident; IQR, interquartile range; OR, odds ratio.
Validity analysis of oculomotor tests according to age and comorbidities in both raters.
| Raters | Sensitivity | Specificity | PPV |
|---|---|---|---|
|
| |||
| <60 years old | 60.0% | 84.2% | 50.0% |
| ≥60 years old | 50.0% | 51.2% | 25.9% |
|
| |||
| <60 years old | 60.0% | 57.9% | 27.3% |
| ≥60 years old | 71.4% | 29.3% | 25.6% |
|
| |||
| Comorbidities: 0 | 40.0% | 100.0% | 100.0% |
| Comorbidities: 1, 2 | 62.5% | 56.3% | 32.3% |
| Comorbidities: ≥3 | 33.3% | 37.5% | 16.7% |
|
| |||
| Comorbidities: 0 | 0.0% | 65.2% | 0.0% |
| Comorbidities: 1, 2 | 87.5% | 35.4% | 31.1% |
| Comorbidities: ≥3 | 66.7% | 25.0% | 25.0% |
Abbreviations: PPV, positive predictive value.